The physicochemical properties, in vitro metabolism and pharmacokinetics of a novel ester prodrug of EXP3174

Molecular Pharmaceutics

Volumn 7, Issue 6, 2010, Pages 2132-2140

  Yan, Yi Dong ^a   Kim, Han Kyung ^b   Seo, Ki Heon ^b   Lee, Won Seok ^a   Lee, Gwan Sun ^b   Woo, Jong Soo ^b   Yong, Chul Soon ^a   Choi, Han Gon ^a,c  

^a Yeungnam University   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; LOSARTAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG STABILITY; DUODENUM; HUMAN; HUMAN TISSUE; ILEUM; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; JEJUNUM; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE;

ANIMALS; CHEMISTRY, PHYSICAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTERS; HUMANS; HYDROGEN-ION CONCENTRATION; IMIDAZOLES; INTESTINES; LIVER; LOSARTAN; MALE; MOLECULAR STRUCTURE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; STEREOISOMERISM; TETRAZOLES; TISSUE DISTRIBUTION;

EID: 78649911815     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100166c     Document Type: Article

References (29)

1. Goa, K. L.; Wagstaff, A. J. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension Drugs 1996, 51, 820-845
2. McIntyre, M.; Caffe, S. E.; Michalak, R. A.; Reid, J. L. Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension Pharmacol. Ther. 1997, 74, 181-194
3. Lo, M. W.; Goldberg, M. R.; McCrea, J. B.; Lu, H.; Furtek, C. I.; Bjornsson, T. D. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans Clin. Pharmacol. Ther. 1995, 58, 641-649
4. Toshiaki, T.; Akira, N.; Shoji, K.; Yawham, A.; Masanori, Y.; Hitoshi, H.; Kyoji, M.; Youichi, A. EXP3 174: The major active metabolite of losartan Cardiovasc. Drug Rev. 1997, 15, 122-136
5. Michel, B. Angiotensin II type 1 receptor blockers Circulation 2001, 103, 904-912
6. Yoshihiro, H.; Rikiya, O.; Koichi, M.; Hiroshi, N. Comparative study of TA-606, a novel angiotensin II receptor antagonist, with losartan in terms of species difference and orthostatic hypotension Jpn. J. Pharmacol. 1999, 81, 63-72
7. Prodrugs: Challenges and rewards; Stella, V. J.; Borchardt, R. T.; Hageman, M.; Oliyai, R.; Maag, H.; Tilley, J., Eds.; AAPS Press/Springer, 2007.
8. Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs J. Med. Chem. 2004, 47, 2393-2404
9. Christa, E. M. Prodrug approaches for enhancing the bioavailability of drugs with low solubility Chem. Biodiversity 2009, 6, 2071-2083
10. Cao, F.; Guo, J. X.; Ping, Q. N.; Liao, Z. G. Prodrugs of scutellarin: ethyle, benzyl andN, N′-Dihydroxyamidine ester synthesis, physicochemical properties, intestinal metabolism and oral bioavailability in the rats Eur. J. Pharm. Sci. 2006, 29, 385-393
11. Mizen, L.; Burton, G. The use of esters as prodrugs for oral delivery of beta-lactam antibiotics Pharm. Biotechnol. 1998, 11, 11345-11365
12. Darkes, M. J. M.; Plosker, G. L. Cefditoren Pivoxil Drugs 2002, 62, 319-336
13. John., M. C.; Daniel, H. L.; Cynthia, B.; Eugene., J. E.; Kenneth, C. C.; Julie, W.; Jay, T.; Craig, G. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil, in chronically hepatitis virus-infected woodchucks Antimicrob. Agents Chemother. 2001, 45, 2740-2745
14. Yasuko, M.; Tokio, S.; Tetsuya, I.; Naruji, S.; Norihisa, K. Carnitine-associated encephalopathy caused by long-term treatment with an antibiotic containing pivalic acid Pediatrics 2007, 120, 739-741
15. Eric, P. B. Pivalate-generating prodrugs and carnitine homeostasis in man Pharmacol. Rev. 2002, 54, 589-598
16. Testa, B. Prodrug research: futile or fertile Biochem. Pharmacol. 2004, 68, 2097-2106
17. Society of Toxicology (SOT). Guiding principles in the use of animals in toxicology: www.toxicology.org/AI/FA/guidingprinciples.pdf. 2008.
18. Griffiths, R.; Lewis, A.; Jeffrey, P. Models of drug absorption in situ and in conscious animals Pharm. Biotechnol. 1996, 8, 67-84
19. Marathe, P. H.; Kamath, A. V.; Zhang, Y. P.; Arienzo, C. D.; Bhide, R.; Fargnoli, J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate Cancer Chemother. Pharmacol. 2009, 65, 55-66
20. Lindahl, A.; Sjoberg, A.; Bredberg, U.; Toreson, H.; Ungell, A. L.; Lennerna, H. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2 Mol. Pharmaceutics 2004, 5, 347-356
21. Kararli, T. T. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals Biopharm. Drug Dispos. 1995, 16, 351-380
22. Choi, Y.; Kim, J. K.; Eunmi, B.; Park, J. S.; Kim, C. K. Determination of losartan in human plasma by liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS): application to bioequivalence study J. Liq. Chromatogr. Relat. Technol. 2008, 31, 2643-2656
23. Moon, C. H.; Lee, H. J.; Lee, S. H.; Baik, E. J. Pharmacokinetics of losartan and its metabolite, EXP3174, after intravenous and oral administration of losartan to rats with streptozotocin-induced diabetes mellitus Res. Commum. Mol. Pathol. Pharmacol. 1998, 101, 147-158
24. Philip, A. K.; Adria, E. C.; Randall, R. M.; Ralph, A. S. Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine J. Pharmacol. Exp. Ther. 1995, 273, 816-822
25. Wong, P. C.; Barnes, T. B.; Chiu, A. T.; Christ, D. D.; Duncia, J. V.; Herblin, W. F.; Timermans, P. B. M. W. M. Losartan (DuP 753), an orally active nonpeptide angiotensin II receptor antagonist Cardiovasc. Drug Rev. 1991, 9, 317-339
26. 1 antagonist losartan as well as its main and active metabolite EXP3174 in biological material of humans and rats J. Pharm. Biomed. Anal. 1998, 16, 863-873
27. Raul, H. L.; Nicholas, F.; Juan, J. L. L.; Sunil., K. A.; William, J. G.; Krishna, C. A. Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue Antimicrob. Agents Chemother. 1993, 37, 818-824
28. Munafo, A.; Christen, Y.; Nussberger, J.; Shum, L. Y.; Borland, R. M.; Lee, R. J.; Waeber, B.; Biollaz, J.; Brunner, H. R. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist Clin. Pharmacol. Ther. 1992, 51, 513-521
29. Lankford, S. M.; Plummer, D.; Hellyer, P.; Christ, D. D.; Bai, S. A. Pharmacokinetic-pharmacodynamic relations of losartan and EXP3174 in a porcine animal model J. Cardiovasc. Pharmacol. 1997, 30, 583-590